


Supplementary Figure 26



Supplementary Figure S26. Removal of mutant TP53 does not impact the *in vivo* growth of the WCB139T human colon cancer derived organoids

A. Growth of the WCB139T human colon cancer derived organoids, either mutant TP53 expressing control cancer cells or their mutant TP53-deleted derivatives, in NSG mice (N=6 mice per organoid line) with tumor volume presented in mm³. **B.** Weights of the tumors from (A) at the ethical endpoint. Data in (A) and (B) are presented as mean±SEM from 6 independent mice for each type of cancer cell. **C.** Western blot analysis of the tumors from (A) to verify the presence of mutant TP53 in the control cancer cells or its absence in their mutant TP53 deleted derivatives. Probing for β-ACTIN was used as a protein loading control. Each lane contains the lysate from an independent tumor. The Western blot shown is representative of 2 independent blots from independent experiments. **D.** H&E staining and IHC of the tumors from (A) to verify the presence of mutant TP53 in the control cancer cells or its absence in the tumors generated from their mutant TP53 deleted derivatives. IHC staining for Ki67 in the tumors from (A) to reveal the expression of this marker of cell proliferation in the control mutant TP53 expressing colon cancer cells and their mutant TP53 deleted derivatives. Magnification 200X.